P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202

• P. Voorhees,
• V. Suman,
• Y. Efebera,
• N. Raje,
• S. Tuchman,
• C. Rodriguez,
• K. Santo,
• M. Bova-Solem,
• D. Carlisle,
• U. Saad,
• P. McCarthy,
• P. Richardson

Affiliations

P. Voorhees

1 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte

V. Suman

2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester

Y. Efebera

3 Department of Hematology and Oncology, Ohio Health, Columbus

N. Raje

4 Division of Hematology and Oncology, Massachusetts General Hospital, HArvard Medical School, Boston

S. Tuchman

5 Division of Hematology, Lineberger Comprehensive Cancer Center, the University of North Carolina, Chapel Hill

C. Rodriguez

6 Tisch Cancer Institute, Mount Sinai School of Medicine, New York City

K. Santo

2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester

M. Bova-Solem

7 Protocol Operations Program, Alliance for Clinical Trials in Oncology, Chicago

D. Carlisle

7 Protocol Operations Program, Alliance for Clinical Trials in Oncology, Chicago

U. Saad

8 Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York City

P. McCarthy

9 Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo

P. Richardson

10 Department of Hematology and Oncology, Dana Farber Cancer Institute / Partners Cancer Care, Harvard Medical School, Boston, United States of America